CN102988392B - Application of Houttuynoid B in preparation of medicine for rising red blood cells - Google Patents
Application of Houttuynoid B in preparation of medicine for rising red blood cells Download PDFInfo
- Publication number
- CN102988392B CN102988392B CN201210469134.9A CN201210469134A CN102988392B CN 102988392 B CN102988392 B CN 102988392B CN 201210469134 A CN201210469134 A CN 201210469134A CN 102988392 B CN102988392 B CN 102988392B
- Authority
- CN
- China
- Prior art keywords
- houttuynoid
- blood cells
- preparation
- application
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention relates to a new application of a compound Houttuynoid B in the field of pharmacy, and particularly relates to an application of Houttuynoid B to preparation of a medicine for rising white blood cells, which is made public for the first time. As a framework type is brand-new, and the inhibitory activity of the Houttuynoid B to low red blood cells is unexpectedly strong, the possibility of obtaining any revelation from other compounds does not exist, and the Houttuynoid B has remarkable substantive distinguishing features and obviously has a notable progress to prevention and treatment of the low red blood cells.
Description
Technical field
The present invention relates to the new purposes of a kind of compound H outtuynoid B in pharmaceutical field.
Background technology
The compound H outtuynoid B the present invention relates to is one and within 2012, delivers (Cai, J.Y.et al., 2012.Houttuynoid B, a Potent Defensive Limonoid, with a New Carbon Skeleton from Aphanamixis polystachya.Organic Letters14 (10), 2524 – 2527.) New skeleton compound, this compound has brand-new framework types, current purposes only relates to DEF(Cai, J.Y.et al., 2012.Houttuynoid B, a Potent Defensive Limonoid, with a New Carbon Skeleton from Aphanamixis polystachya.Organic Letters14 (10), 2524 – 2527.), purposes for the Houttuynoid B the present invention relates in the low medicine thing of preparation treatment erythrocyte belongs to open first, because framework types belongs to brand-new framework types, and it lowly suppresses active unexpectedly strong for erythrocyte, there do not is the possibility that is provided any enlightenment by other compounds, possesses outstanding substantive distinguishing features, for erythrocyte, low control obviously has significant progress simultaneously.
Summary of the invention
The object of the present invention is to provide the new application of Houttuynoid B in pharmaceutical field.
The present invention relates to Houttuynoid B as the application in the erythrocytic medicine of preparation rising.
Described compound H outtuynoid B structure is as shown in formula I:
The purposes of the Houttuynoid B the present invention relates in the low medicine thing of preparation treatment erythrocyte belongs to open first, because framework types belongs to brand-new framework types, and it lowly suppresses active unexpectedly strong for erythrocyte, there do not is the possibility that is provided any enlightenment by other compounds, possess outstanding substantive distinguishing features, for erythrocyte, low control obviously has significant progress simultaneously.
The specific embodiment
The preparation method of compound H outtuynoid B involved in the present invention is referring to document (Cai, J.Y.et al., 2012.Houttuynoid B, a Potent Defensive Limonoid, with a New Carbon Skeleton from Aphanamixis polystachya.Organic Letters14 (10), 2524 – 2527.).
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subject to any restriction of specific embodiment, but be limited by claim.
Embodiment 1: the preparation of compound H outtuynoid B tablet involved in the present invention:
Get 20 and digest compound Houttuynoid B, add conventional adjuvant 180 grams that prepare tablet, mix, conventional tablet machine is made 1000.
Embodiment 2: the preparation of compound H outtuynoid B capsule involved in the present invention:
Get 20 and digest compound Houttuynoid B, add the conventional adjuvant for preparing capsule as starch 180 grams, mix, encapsulatedly make 1000.
Further illustrate its pharmaceutically active below by pharmacodynamic experiment.
In order to understand better essence of the present invention, below will its new purposes in pharmaceutical field be described by drug test and the result of Houttuynoid B.
The hemoposieis of Houttuynoid B:
One, the therapeutical effect of Houttuynoid B to the mice that loses blood
On the mice that loses blood affect 40 of ICR mices, ♀ ♂ half and half, be divided into 4 groups (n=10).Except the normal saline group, every mice of other group, from eye socket venesection 0.5ml, is got the blood survey again and all respectively organizes index after 24h, and then continuous gastric infusion is 1 week, after last administration 1h, gets blood from the eye socket venous plexus and surveys These parameters with F-800 whole blood platelet analyser.
Table 1Houttuynoid B is to because of oligocythemic therapeutical effect due to losing blood
With model group, compare: * p<0.05**p<0.01***p<0.001
Result shows, the blood-letting mice is through taking Houttuynoid B treatment after 7 days, and respectively at model group relatively, its erythrocyte is significantly higher than model group to 2 administration groups, approaches the normal saline group.
Two, Houttuynoid B causes oligocythemic therapeutical effect to cyclophosphamide
To 40 of the preventive and therapeutic effect ICR mices of mouse bone marrow cells hemopoietic function damage, ♀ ♂ dual-purpose, be divided into 4 groups (n=10), i.e. normal saline group, modeling group, 1.2mg/kg group and 0.6mg/kg group, oral administration, every day 1 time.0th, except the normal saline group, other respectively organized mice lumbar injection cycli phosphate amine 80mg/kg respectively, then continued administration 3 days on 5th, 10.1h after the last administration, get blood from the eye socket venous plexus, surveys erythrocyte, gets femur bone marrow counting number of nucleated cells.
Table 2Houttuynoid B is on the erythrocytic impact of caused by cyclophosphamide
With the normal saline group, compare: * p<0.05**p<0.01***p<0.001
Result shows, with the normal saline group, compares, and cycli phosphate amine can make the mouse bone marrow cells damage, causes peripheral blood cells to descend, and Houttuynoid B group compares with model group, all can obviously resist the red decline of cycli phosphate amine induced mice.
Three, Houttuynoid B is to oligocythemic therapeutical effect due to stupid
Impact on Induced Aplastic Anemia Mice: 48 of Kunming mouses, ♀ ♂ dual-purpose, be divided into 4 groups (n=12), except the normal saline group, other group mouse subcutaneous injection benzene 0.5ml/kg, continuous 12 days, the same day of modeling, the while oral administration, every day 1 time, totally 18 days, 1h after the last administration, the eye socket venous plexus is got blood, surveys erythrocyte, gets femur bone marrow counting number of nucleated cells.
Table 3Houttuynoid B is to oligocythemic therapeutical effect due to benzene
With model group, compare: * p<0.05**p<0.01***p<0.001
Result shows, 2 administration groups respectively at model group relatively, all can obviously be resisted the erythrocytic decline of Induced Aplastic Anemia Mice due to benzene.
Four, Houttuynoid B is to oligocythemic therapeutical effect due to radiation
For the therapeutical effect of research to acute radiation sickness, the Houttuynoid B that has observed various dose irradiates on 6.5Gy the impact that mouse hemopoietic recovers.
Table 4Houttuynoid B is to oligocythemic therapeutical effect (the 10th day) due to radiation
With the modeling group, compare: * p<0.05**p<0.01***p<0.001
Result shows, give be subject to according to mice Houttuynoid every day B0.1,0.5 and the 2.0mg/kg treatment after, the recovery model of peripheral red blood cells is accelerated, and take 2.0mg dosage group effect as best.
Conclusion: the Houttuynoid B erythrocyte that can significantly raise can be used for the preparation erythrocytic medicine that raises.
Claims (1)
1.Houttuynoid the application of B in preparation raises erythrocytic medicine, described compound H outtuynoid B structure as
formula Ishown in:
formula I.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210469134.9A CN102988392B (en) | 2012-11-19 | 2012-11-19 | Application of Houttuynoid B in preparation of medicine for rising red blood cells |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210469134.9A CN102988392B (en) | 2012-11-19 | 2012-11-19 | Application of Houttuynoid B in preparation of medicine for rising red blood cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102988392A CN102988392A (en) | 2013-03-27 |
| CN102988392B true CN102988392B (en) | 2014-01-01 |
Family
ID=47917820
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210469134.9A Expired - Fee Related CN102988392B (en) | 2012-11-19 | 2012-11-19 | Application of Houttuynoid B in preparation of medicine for rising red blood cells |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102988392B (en) |
-
2012
- 2012-11-19 CN CN201210469134.9A patent/CN102988392B/en not_active Expired - Fee Related
Non-Patent Citations (4)
| Title |
|---|
| Houttuynoids A-E,anti-herpes simplex virus active flavonoids with novel skeletons from houttuynia cordata;Shao-dan Chen et al.;《Organic Letters》;20120313;第14卷(第7期);第1772-1775页 * |
| Shao-danChenetal..HouttuynoidsA-E anti-herpes simplex virus active flavonoids with novel skeletons from houttuynia cordata.《Organic Letters》.2012 |
| 复方鱼腥草口服液对辐射损伤后小鼠外周血相的影响;胡麟等;《现代医药卫生》;20011231;第17卷(第07期);第514-515页 * |
| 胡麟等.复方鱼腥草口服液对辐射损伤后小鼠外周血相的影响.《现代医药卫生》.2001,第17卷(第07期), |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102988392A (en) | 2013-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103271913A (en) | Application of Myriberine A in preparing thrombocyte-increasing medicines | |
| CN102988392B (en) | Application of Houttuynoid B in preparation of medicine for rising red blood cells | |
| CN102988380B (en) | Application of Houttuynoid B in preparation of medicine for rising white blood cells | |
| CN102872036A (en) | Application of Gypensapogenin A in medicament for increasing level of red blood cells | |
| CN103271917A (en) | Application of Myriberine A in preparing erythrocyte-increasing medicines | |
| CN103356648B (en) | Chukrasone A raises the application in erythrocytic medicine in preparation | |
| CN102872043B (en) | Application of Gypensapogenin B in medicament of increasing level of leukocyte | |
| CN102861024A (en) | Application of Gypensapogenin A in medicine for increasing white blood cell | |
| CN103720686B (en) | Trigoxyphin K is raising the application in erythrocyte medicine | |
| CN103462956B (en) | Application of Nardoaristolones A in preparation of medicaments for increasing erythrocytes | |
| CN103120685A (en) | Application of Aphanamixoid A in medicine for increasing erythrocytes | |
| CN103356642B (en) | The application of Chukrasone A in the medicine preparing leukocyte increasing | |
| CN103372001B (en) | The application of Chukrasone B in the medicine preparing leukocyte increasing | |
| CN103393660A (en) | Application of Sarcaboside B to preparation of medicament for raising erythrocyte | |
| CN103127070A (en) | Application of Eryngiolide A in medicines rising white blood cell | |
| CN103120657A (en) | Application of Eryngiolide A in medicine for increasing red blood cells | |
| CN103372002A (en) | Application of Chukrasone B in preparation of medicines for increasing red blood cells | |
| CN103356555A (en) | Application of Sarcaboside A in erythrocyte-increasing medicines | |
| CN103027919A (en) | Application of Houttuynoid D in preparation of drug for increasing red blood cells | |
| CN103372018B (en) | The application of Chukrasone A in the medicine of preparation increased platelets counts | |
| CN103463105A (en) | Application of Phyllanthoid A in preparing medicament for increasing erythrocytes | |
| CN103127081A (en) | Application of Aphanamixoid A to leukocyte increasing medicine | |
| CN103285011A (en) | Application of Aspeverin in red blood cell increase drug preparation | |
| CN103356566A (en) | Application of Sarcaboside B in leukocyte-increasing medicines | |
| CN103381158A (en) | Applications of Chukrasone B in medicines used for increasing thrombocyte |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140101 Termination date: 20151119 |
|
| EXPY | Termination of patent right or utility model |